Bond.az White LogoBond.az Black Logo

Oppenheimer Reaffirms Analog Devices Stock Rating

Oppenheimer reaffirms Outperform rating for Analog Devices (ADI) amid AI demand and strong quarterly results, with a $450 price target.

Lucas Garcia
ByLucas Garcia- Senior Editor
|
0

Bond.az - Oppenheimer has reiterated an Outperform rating and $450 price target on Analog Devices (ADI) following the company's quarterly results. The decision comes amid rising demand for artificial intelligence.

ADI shares have surged 82% over the past year to $398. However, Bond.az analysis indicates the shares are currently trading above their Fair Value, placing ADI on the platform's Most Overvalued stocks list.

The company reported second fiscal quarter results for April that exceeded Wall Street expectations. Sales and earnings per share beat estimates by 3% and 7% respectively, driven by AI demand in data center communications and automated test equipment within the industrial segment.

The third fiscal quarter outlook for July came in 8% ahead of expectations for revenue and 11% ahead for earnings, with revenue expected to rise 8% sequentially. Data center and automated test equipment strength is expected to continue, while all industrial businesses showed quarter-over-quarter and year-over-year growth.

Data center communications, which represents 75% of the communications segment and 11% of total revenue, rose more than 90% year-over-year. Automotive sales rebounded earlier than expected, with second fiscal quarter growth driven by content and market share gains in advanced driver assistance systems and infotainment.

The company's planned acquisition of Empower expands its addressable market in premium in-vehicle radar and is expected to close this year. Revenue contribution from the acquisition is expected to be minimal this year.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
Oppenheimer Reaffirms Analog Devices Stock Rating | Bond.az